EMEA-001808-PIP03-17

Key facts

Active substance
Sarizotan (hydrochloride)
Therapeutic area
Neurology
Decision number
P/0287/2018
PIP number
EMEA-001808-PIP03-17
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral liquid dosage form
Condition(s) / indication(s)
Treatment of Rett syndrome
Route(s) of administration
Oral use
Contact for public enquiries
Newron Pharmaceuticals SpA

E-mail: ravi@anand.ch
Tel. +41 793741364

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating